Literature DB >> 11453897

Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.

C Senda1, Y Yamaura, K Kobayashi, H Fujii, H Minami, Y Sasaki, T Igarashi, K Chiba.   

Abstract

AIMS: To study the influence of CYP2D6*10 on the formation of p-hydroxymexiletine (PHM) and hydroxymethylmexiletine (HMM) using microsomes from human liver of known genotypes.
METHODS: Microsomes from human livers of genotype CYP2D6*1/*1 (n = 5), *1/*10 (n = 6) and *10/*10 (n = 6) were used in this study. The formation of PHM and HMM was determined by high-performance liquid chromatography.
RESULTS: The formation rates of PHM and HMM were decreased by more than 50% and 85% in CYP2D6*1/*10 and *10/*10 microsomes, respectively, compared with *1/*1 microsomes.
CONCLUSIONS: The metabolism of mexiletine to form PHM and HMM appears to be impaired to a significant extent in human liver microsomes from hetero- and homozygotes of CYP2D6*10.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453897      PMCID: PMC2014511          DOI: 10.1046/j.0306-5251.2001.01411.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.

Authors:  T Kubota; Y Yamaura; N Ohkawa; H Hara; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

2.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

Authors:  I Johansson; M Oscarson; Q Y Yue; L Bertilsson; F Sjöqvist; M Ingelman-Sundberg
Journal:  Mol Pharmacol       Date:  1994-09       Impact factor: 4.436

3.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.

Authors:  T Fukuda; I Yamamoto; Y Nishida; Q Zhou; M Ohno; K Takada; J Azuma
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

4.  The kinetic characterization of S-mephenytoin 4-hydroxylase (P-450IICMP) activity in human liver samples obtained as surgical waste from Japanese patients.

Authors:  K Chiba; K Kobayashi; M Tani; K Manabe; T Ishizaki
Journal:  Drug Metab Dispos       Date:  1993 Jul-Aug       Impact factor: 3.922

5.  Propranolol disposition in Chinese subjects of different CYP2D6 genotypes.

Authors:  M L Lai; S L Wang; M D Lai; E T Lin; M Tse; J D Huang
Journal:  Clin Pharmacol Ther       Date:  1995-09       Impact factor: 6.875

6.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

7.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.

Authors:  K Chiba; K Kobayashi; K Manabe; M Tani; T Kamataki; T Ishizaki
Journal:  J Pharmacol Exp Ther       Date:  1993-07       Impact factor: 4.030

8.  The clinical pharmacology of mexiletine.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

9.  Involvement of CYP1A2 in mexiletine metabolism.

Authors:  M Nakajima; K Kobayashi; N Shimada; S Tokudome; T Yamamoto; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

10.  Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.

Authors:  J Turgeon; C Fiset; R Giguère; M Gilbert; K Moerike; J R Rouleau; H K Kroemer; M Eichelbaum; O Grech-Bélanger; P M Bélanger
Journal:  J Pharmacol Exp Ther       Date:  1991-11       Impact factor: 4.030

  10 in total
  3 in total

1.  Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.

Authors:  Amelia Nathania Dong; Nafees Ahemad; Yan Pan; Uma Devi Palanisamy; Beow Chin Yiap; Chin Eng Ong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-26       Impact factor: 3.000

2.  Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.

Authors:  Masahiro Otani; Tsuyoshi Fukuda; Masakazu Naohara; Hiromi Maune; Chiaki Senda; Isamu Yamamoto; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2003-08-23       Impact factor: 2.953

3.  A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.

Authors:  S Ryu; S Park; J H Lee; Y R Kim; H S Na; H S Lim; H Y Choi; I Y Hwang; J G Lee; Z W Park; W Y Oh; J M Kim; S E Choi
Journal:  Clin Transl Sci       Date:  2017-03-14       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.